

Submission of comments on 21.08.17

Submission of comments on Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol EMA/430909/2016

## **Comments from:**

Name of organisation or individual

## **EUROPEAN INDUSTRIAL PHARMACISTS GROUP (EIPG)**

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

When completed, this form should be sent to the European Medicines Agency electronically, in Word format (not PDF).



## 1. General comments

| Stakeholder number              | General comment (if any)   | Outcome (if applicable)         |
|---------------------------------|--|---------------------------------|
| (To be completed by the Agency) |  | (To be completed by the Agency) |
|                                 | Appendix 1 page 8 (IMP) sentence on detail of breach: "5) Due to an interactive response technologies (IRT) malfunction 50% of subjects assigned to one arm were unblinded in a blinded trial, furthermore this information was submitted to all trial staff at all investigator sites participating in the trial"  Obviously this was a systematic issue that impacts the robustness and reliability of the data but please clarify why this could potentially affect the safety of trial subjects. |                                 |
|                                 | General comment on the document:  Trial subjects take many risks, and must be given the opportunity to play an active role in safeguarding their own interests, including the ability to report SAEs or SUSARs directly.  The document should state that when a serious breach is considered to impact the safety of trial subjects, all subjects in the trial should receive information on the breach.   |                                 |

## 2. Specific comments on text

| Line number(s) of  | Stakeholder number  | Comment and rationale; proposed changes                  | Outcome                         |
|--------------------|---------------------|--|---------------------------------|
| the relevant text  | (To be completed by | (If changes to the wording are suggested, they should be | (To be completed by the Agency) |
| (e.g. Lines 20-23) | the Agency)         | highlighted using 'track changes')                       |                                 |
| Lines 87-90        |                     | Comment: Clarify with examples.                          |                                 |
|                    |                     | Proposed change (if any):                                |                                 |
|                    |                     | Comment:   |                                 |
|                    |                     | Proposed change (if any):                                |                                 |
|                    |                     | Comment:   |                                 |
|                    |                     | Proposed change (if any):                                |                                 |